The PE Ratio as of November 2024 (TTM) for Context Therapeutics Inc. (CNTX) is -1.58

According to Context Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.58. This represents a change of -59.08% compared to the average of -3.86 of the last 4 quarters.

Context Therapeutics Inc. (CNTX) Historical PE Ratio (quarterly & annually)

How has CNTX PE Ratio performed in the past?

The mean historical PE Ratio of Context Therapeutics Inc. over the last ten years is -1.25. The current -1.58 PE Ratio has changed 12.54% with respect to the historical average. Over the past ten years (40 quarters), CNTX's PE Ratio was at its highest in in the March 2020 quarter at 6.73. The PE Ratio was at its lowest in in the December 2020 quarter at -16.59.

Context Therapeutics Inc. (CNTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Context Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Context Therapeutics Inc. (CNTX) Average PE Ratio

How has CNTX PE Ratio performed in the past?

The current PE Ratio of Context Therapeutics Inc. (CNTX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Context Therapeutics Inc. (CNTX) PE Ratio vs. Peers

How is CNTX’s PE Ratio compared to its peers?

Context Therapeutics Inc.’s PE Ratio is greater than Terns Pharmaceuticals, Inc. (-5.12), less than Amylyx Pharmaceuticals, Inc. (-1.38), greater than Acumen Pharmaceuticals, Inc. (-1.74), greater than Inozyme Pharma, Inc. (-1.84), greater than X4 Pharmaceuticals, Inc. (-4.05), less than Spero Therapeutics, Inc. (21.41), less than Bolt Biotherapeutics, Inc. (-0.34), greater than Coherus BioSciences, Inc. (-279.06), greater than Gracell Biotechnologies Inc. (-29.05), greater than Neoleukin Therapeutics, Inc. (-5.86), greater than Day One Biopharmaceuticals, Inc. (-15.73), greater than VectivBio Holding AG (-7.94), less than NextCure, Inc. (-0.57), less than CytomX Therapeutics, Inc. (5.48), greater than Assembly Biosciences, Inc. (-2.34), greater than Zura Bio Limited (-5.60), greater than Annexon, Inc. (-6.12), greater than Icosavax, Inc. (-15.78), less than IN8bio, Inc. (-0.47), greater than Wave Life Sciences Ltd. (-13.27),

Build a custom stock screener for Context Therapeutics Inc. (CNTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Context Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Context Therapeutics Inc. (CNTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Context Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.